A direct comparison of endothelial progenitor cell dysfunction in rat metabolic syndrome and diabetes

Atherosclerosis

Volumn 226, Issue 1, 2013, Pages 58-66

  Kuliszewski, Michael A ^a   Ward, Michael R ^a   Kowalewski, James W ^a   Smith, Alexandra H ^a   Stewart, Duncan J ^b   Kutryk, Michael J ^a   Leong Poi, Howard ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Angiogenesis; Diabetes; Endothelial progenitor cells; Metabolic syndrome

Indexed keywords

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL MIGRATION; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIAL PROGENITOR CELL; IN VITRO STUDY; IN VIVO STUDY; LIMB ISCHEMIA; MALE; METABOLIC SYNDROME X; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; MALE; METABOLIC SYNDROME X; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, ZUCKER; STEM CELLS;

EID: 84871366064     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.09.029     Document Type: Article

References (31)

1. Asahara T., Masuda H., Takahashi T., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999, 85:221-228.
2. Hill J.M., Zalos G., Halcox J.P., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003, 348:593-600.
3. Kunz G.A., Liang G., Cuculi F., et al. Circulating endothelial progenitor cells predict coronary artery disease severity. Am Heart J 2006, 152:190-195.
4. Fadini G.P., Agostini C., Sartore S., Avogaro A. Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis 2007, 194:46-54.
5. Werner N., Nickenig G. Clinical and therapeutical implications of EPC biology in atherosclerosis. J Cell Mol Med 2006, 10:318-332.
6. Fadini G.P., Sartore S., Albiero M., et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol 2006, 26:2140-2146.
7. Tepper O.M., Galiano R.D., Capla J.M., et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002, 106:2781-2786.
8. Albiero M., Menegazzo L., Boscaro E., Agostini C., Avogaro A., Fadini G.P. Defective recruitment, survival and proliferation of bone marrow-derived progenitor cells at sites of delayed diabetic wound healing in mice. Diabetologia 2011, 54:945-953.
9. Grundy S.M. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008, 28:629-636.
10. Mente A., Yusuf S., Islam S., et al. Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. J Am Coll Cardiol 2010, 55:2390-2398.
11. Fadini G.P., de Kreutzenberg S.V., Coracina A., et al. Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk. Eur Heart J 2006, 27:2247-2255.
12. Jialal I., Devaraj S., Singh U., Huet B.A. Decreased number and impaired functionality of endothelial progenitor cells in subjects with metabolic syndrome: implications for increased cardiovascular risk. Atherosclerosis 2010, 211:297-302.
13. Westerweel P.E., Visseren F.L., Hajer G.R., et al. Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy. Eur Heart J 2008, 29:2808-2817.
14. Fadini G.P., de Kreutzenberg S., Agostini C., et al. Low CD34+ cell count and metabolic syndrome synergistically increase the risk of adverse outcomes. Atherosclerosis 2009, 207:213-219.
15. Fadini G.P., Agostini C., Boscaro E., Avogaro A. Mechanisms and significance of progenitor cell reduction in the metabolic syndrome. Metab Syndr Relat Disord 2009, 7:5-10.
16. Devaraj S., Jialal I. Dysfunctional endothelial progenitor cells in metabolic syndrome. Exp Diabetes Res 2012, 585018.
17. Sanchez A., Contreras C., Martinez P., et al. Enhanced cyclooxygenase 2-mediated vasorelaxation in coronary arteries from insulin-resistant obese Zucker rats. Atherosclerosis 2010, 213:392-399.
18. Takenaka T., Inoue T., Okada H., et al. Altered gap junctional communication and renal haemodynamics in Zucker fatty rat model of type 2 diabetes. Diabetologia 2011, 54:2192-2201.
19. Beltowski J., Atanassova P., Chaldakov G.N., Jamroz-Wisniewska A., Kula W., Rusek M. Opposite effects of pravastatin and atorvastatin on insulin sensitivity in the rat: role of vitamin D metabolites. Atherosclerosis 2011, 219:526-531.
20. Kuliszewski M.A., Kobulnik J., Lindner J.R., Stewart D.J., Leong-Poi H. Vascular gene transfer of SDF-1 promotes endothelial progenitor cell engraftment and enhances angiogenesis in ischemic muscle. Mol Ther 2011, 19:895-902.
21. Thum T., Fraccarollo D., Schultheiss M., et al. Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes 2007, 56:666-674.
22. Satoh M., Ishikawa Y., Takahashi Y., Itoh T., Minami Y., Nakamura M. Association between oxidative DNA damage and telomere shortening in circulating endothelial progenitor cells obtained from metabolic syndrome patients with coronary artery disease. Atherosclerosis 2008, 198:347-353.
23. Gallagher K.A., Liu Z.J., Xiao M., et al. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest 2007, 117:1249-1259.
24. Jialal I., Fadini G.P., Pollock K., Devaraj S. Circulating levels of endothelial progenitor cell mobilizing factors in the metabolic syndrome. Am J Cardiol 2010, 106:1606-1608.
25. Schachinger V., Erbs S., Elsasser A., et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006, 355:1210-1221.
26. Wollert K.C., Meyer G.P., Lotz J., et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004, 364:141-148.
27. Napoli C., Hayashi T., Cacciatore F., et al. Endothelial progenitor cells as therapeutic agents in the microcirculation: an update. Atherosclerosis 2011, 215:9-22.
28. Schachinger V., Erbs S., Elsasser A., et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J 2006, 27:2775-2783.
29. Landmesser U., Engberding N., Bahlmann F.H., et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004, 110:1933-1939.
30. Werner C., Kamani C.H., Gensch C., Bohm M., Laufs U. The PPAR-{gamma} agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes 2007.
31. Taljaard M., Ward M.R., Kutryk M.J., et al. Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI): the first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction. Am Heart J 2010, 159:354-360.